This research report focuses on the Adalimumab Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.
TABLE OF CONTENTS
1 Study Coverage
- 1.1 Adalimumab Product Introduction
- 1.2 Market by Type
- 1.2.1 Global Adalimumab Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
- 1.2.2 Adalimumab
- 1.2.3 Adalimumab Biosimilar
- 1.3 Market by Application
- 1.3.1 Global Adalimumab Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
- 1.3.2 Adults
- 1.3.3 Children
- 1.4 Study Objectives
- 1.5 Years Considered
2 Executive Summary
- 2.1 Global Adalimumab Sales Estimates and Forecasts 2017-2028
- 2.2 Global Adalimumab Revenue Estimates and Forecasts 2017-2028
- 2.3 Global Adalimumab Revenue by Region: 2017 VS 2021 VS 2028
- 2.4 Global Adalimumab Sales by Region
- 2.4.1 Global Adalimumab Sales by Region (2017-2022)
- 2.4.2 Global Sales Adalimumab by Region (2023-2028)
- 2.5 Global Adalimumab Revenue by Region
- 2.5.1 Global Adalimumab Revenue by Region (2017-2022)
- 2.5.2 Global Adalimumab Revenue by Region (2023-2028)
- 2.6 North America
- 2.7 Europe
- 2.8 Asia-Pacific
- 2.9 Latin America
- 2.10 Middle East & Africa
3 Competition by Manufacturers
- 3.1 Global Adalimumab Sales by Manufacturers
- 3.1.1 Global Top Adalimumab Manufacturers by Sales (2017-2022)
- 3.1.2 Global Adalimumab Sales Market Share by Manufacturers (2017-2022)
- 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Adalimumab in 2021
- 3.2 Global Adalimumab Revenue by Manufacturers
- 3.2.1 Global Adalimumab Revenue by Manufacturers (2017-2022)
- 3.2.2 Global Adalimumab Revenue Market Share by Manufacturers (2017-2022)
- 3.2.3 Global Top 10 and Top 5 Companies by Adalimumab Revenue in 2021
- 3.3 Global Adalimumab Sales Price by Manufacturers (2017-2022)
- 3.4 Analysis of Competitive Landscape
- 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Adalimumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4.3 Global Adalimumab Manufacturers Geographical Distribution
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Global Adalimumab Sales by Type
- 4.1.1 Global Adalimumab Historical Sales by Type (2017-2022)
- 4.1.2 Global Adalimumab Forecasted Sales by Type (2023-2028)
- 4.1.3 Global Adalimumab Sales Market Share by Type (2017-2028)
- 4.2 Global Adalimumab Revenue by Type
- 4.2.1 Global Adalimumab Historical Revenue by Type (2017-2022)
- 4.2.2 Global Adalimumab Forecasted Revenue by Type (2023-2028)
- 4.2.3 Global Adalimumab Revenue Market Share by Type (2017-2028)
- 4.3 Global Adalimumab Price by Type
- 4.3.1 Global Adalimumab Price by Type (2017-2022)
- 4.3.2 Global Adalimumab Price Forecast by Type (2023-2028)
5 Market Size by Application
- 5.1 Global Adalimumab Sales by Application
- 5.1.1 Global Adalimumab Historical Sales by Application (2017-2022)
- 5.1.2 Global Adalimumab Forecasted Sales by Application (2023-2028)
- 5.1.3 Global Adalimumab Sales Market Share by Application (2017-2028)
- 5.2 Global Adalimumab Revenue by Application
- 5.2.1 Global Adalimumab Historical Revenue by Application (2017-2022)
- 5.2.2 Global Adalimumab Forecasted Revenue by Application (2023-2028)
- 5.2.3 Global Adalimumab Revenue Market Share by Application (2017-2028)
- 5.3 Global Adalimumab Price by Application
- 5.3.1 Global Adalimumab Price by Application (2017-2022)
- 5.3.2 Global Adalimumab Price Forecast by Application (2023-2028)
6 North America
- 6.1 North America Adalimumab Market Size by Type
- 6.1.1 North America Adalimumab Sales by Type (2017-2028)
- 6.1.2 North America Adalimumab Revenue by Type (2017-2028)
- 6.2 North America Adalimumab Market Size by Application
- 6.2.1 North America Adalimumab Sales by Application (2017-2028)
- 6.2.2 North America Adalimumab Revenue by Application (2017-2028)
- 6.3 North America Adalimumab Market Size by Country
- 6.3.1 North America Adalimumab Sales by Country (2017-2028)
- 6.3.2 North America Adalimumab Revenue by Country (2017-2028)
- 6.3.3 U.S.
- 6.3.4 Canada
7 Europe
- 7.1 Europe Adalimumab Market Size by Type
- 7.1.1 Europe Adalimumab Sales by Type (2017-2028)
- 7.1.2 Europe Adalimumab Revenue by Type (2017-2028)
- 7.2 Europe Adalimumab Market Size by Application
- 7.2.1 Europe Adalimumab Sales by Application (2017-2028)
- 7.2.2 Europe Adalimumab Revenue by Application (2017-2028)
- 7.3 Europe Adalimumab Market Size by Country
- 7.3.1 Europe Adalimumab Sales by Country (2017-2028)
- 7.3.2 Europe Adalimumab Revenue by Country (2017-2028)
- 7.3.3 Germany
- 7.3.4 France
- 7.3.5 U.K.
- 7.3.6 Italy
- 7.3.7 Russia
8 Asia Pacific
- 8.1 Asia Pacific Adalimumab Market Size by Type
- 8.1.1 Asia Pacific Adalimumab Sales by Type (2017-2028)
- 8.1.2 Asia Pacific Adalimumab Revenue by Type (2017-2028)
- 8.2 Asia Pacific Adalimumab Market Size by Application
- 8.2.1 Asia Pacific Adalimumab Sales by Application (2017-2028)
- 8.2.2 Asia Pacific Adalimumab Revenue by Application (2017-2028)
- 8.3 Asia Pacific Adalimumab Market Size by Region
- 8.3.1 Asia Pacific Adalimumab Sales by Region (2017-2028)
- 8.3.2 Asia Pacific Adalimumab Revenue by Region (2017-2028)
- 8.3.3 China
- 8.3.4 Japan
- 8.3.5 South Korea
- 8.3.6 India
- 8.3.7 Australia
- 8.3.8 Taiwan
- 8.3.9 Indonesia
- 8.3.10 Thailand
- 8.3.11 Malaysia
- 8.3.12 Philippines
9 Latin America
- 9.1 Latin America Adalimumab Market Size by Type
- 9.1.1 Latin America Adalimumab Sales by Type (2017-2028)
- 9.1.2 Latin America Adalimumab Revenue by Type (2017-2028)
- 9.2 Latin America Adalimumab Market Size by Application
- 9.2.1 Latin America Adalimumab Sales by Application (2017-2028)
- 9.2.2 Latin America Adalimumab Revenue by Application (2017-2028)
- 9.3 Latin America Adalimumab Market Size by Country
- 9.3.1 Latin America Adalimumab Sales by Country (2017-2028)
- 9.3.2 Latin America Adalimumab Revenue by Country (2017-2028)
- 9.3.3 Mexico
- 9.3.4 Brazil
- 9.3.5 Argentina
10 Middle East and Africa
- 10.1 Middle East and Africa Adalimumab Market Size by Type
- 10.1.1 Middle East and Africa Adalimumab Sales by Type (2017-2028)
- 10.1.2 Middle East and Africa Adalimumab Revenue by Type (2017-2028)
- 10.2 Middle East and Africa Adalimumab Market Size by Application
- 10.2.1 Middle East and Africa Adalimumab Sales by Application (2017-2028)
- 10.2.2 Middle East and Africa Adalimumab Revenue by Application (2017-2028)
- 10.3 Middle East and Africa Adalimumab Market Size by Country
- 10.3.1 Middle East and Africa Adalimumab Sales by Country (2017-2028)
- 10.3.2 Middle East and Africa Adalimumab Revenue by Country (2017-2028)
- 10.3.3 Turkey
- 10.3.4 Saudi Arabia
11 Company Profiles
- 11.1 AbbVie
- 11.1.1 AbbVie Corporation Information
- 11.1.2 AbbVie Overview
- 11.1.3 AbbVie Adalimumab Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.1.4 AbbVie Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
- 11.1.5 AbbVie Recent Developments
- 11.2 Amgen
- 11.2.1 Amgen Corporation Information
- 11.2.2 Amgen Overview
- 11.2.3 Amgen Adalimumab Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.2.4 Amgen Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
- 11.2.5 Amgen Recent Developments
- 11.3 Sandoz
- 11.3.1 Sandoz Corporation Information
- 11.3.2 Sandoz Overview
- 11.3.3 Sandoz Adalimumab Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.3.4 Sandoz Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
- 11.3.5 Sandoz Recent Developments
- 11.4 Boehringer Ingelheim
- 11.4.1 Boehringer Ingelheim Corporation Information
- 11.4.2 Boehringer Ingelheim Overview
- 11.4.3 Boehringer Ingelheim Adalimumab Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.4.4 Boehringer Ingelheim Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
- 11.4.5 Boehringer Ingelheim Recent Developments
- 11.5 Mylan
- 11.5.1 Mylan Corporation Information
- 11.5.2 Mylan Overview
- 11.5.3 Mylan Adalimumab Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.5.4 Mylan Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
- 11.5.5 Mylan Recent Developments
- 11.6 Biogen
- 11.6.1 Biogen Corporation Information
- 11.6.2 Biogen Overview
- 11.6.3 Biogen Adalimumab Sales, Price, Revenue and Gross Margin (2017-2022)
- 11.6.4 Biogen Adalimumab Product Model Numbers, Pictures, Descriptions and Specifications
- 11.6.5 Biogen Recent Developments
12 Industry Chain and Sales Channels Analysis
- 12.1 Adalimumab Industry Chain Analysis
- 12.2 Adalimumab Key Raw Materials
- 12.2.1 Key Raw Materials
- 12.2.2 Raw Materials Key Suppliers
- 12.3 Adalimumab Production Mode & Process
- 12.4 Adalimumab Sales and Marketing
- 12.4.1 Adalimumab Sales Channels
- 12.4.2 Adalimumab Distributors
- 12.5 Adalimumab Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
- 13.1 Adalimumab Industry Trends
- 13.2 Adalimumab Market Drivers
- 13.3 Adalimumab Market Challenges
- 13.4 Adalimumab Market Restraints
14 Key Findings in The Global Adalimumab Study
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.2 Data Source
- 15.2 Author Details
- 15.3 Disclaimer